Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
Cynata’s iPSC-derived Cell Therapeutic
(CYP-001) Meets Safety & Efficacy Endpoints
Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]
Parkinson’s Disease Clinical Trial to Launch in Japan | iPS Cell Trial
Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.
Existing iPS Cell Trials
This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]
Dr. Paul Wotton on the Future of Cynata Therapeutics’ Novel iPSC-Derived MSCs
This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. [Read more…]
Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells
Hamburg, June 2018Â –Â Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has expeÂrienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell appliÂcations including regenerative medicine. [Read more…]
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 78
- Next Page »